Elanco Animal Health Incorporated (NYSE:ELAN) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Elanco Animal Health Incorporated (NYSE:ELAN) have been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $17.57.

A number of analysts have commented on ELAN shares. Barclays cut their price target on shares of Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating for the company in a research note on Friday, June 28th. Piper Sandler cut their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating for the company in a research note on Monday, July 1st.

Insider Buying and Selling

In other news, Director William F. Doyle acquired 15,000 shares of the stock in a transaction on Tuesday, May 21st. The shares were purchased at an average price of $16.98 per share, for a total transaction of $254,700.00. Following the transaction, the director now directly owns 76,330 shares of the company’s stock, valued at $1,296,083.40. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. 0.57% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its position in shares of Elanco Animal Health by 0.8% in the second quarter. Bank of New York Mellon Corp now owns 2,289,916 shares of the company’s stock worth $33,043,000 after purchasing an additional 17,486 shares during the period. AMG National Trust Bank grew its position in Elanco Animal Health by 6.3% in the second quarter. AMG National Trust Bank now owns 129,665 shares of the company’s stock valued at $1,871,000 after acquiring an additional 7,641 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in Elanco Animal Health in the second quarter valued at about $158,000. Raymond James & Associates grew its position in Elanco Animal Health by 2.3% in the second quarter. Raymond James & Associates now owns 1,240,909 shares of the company’s stock valued at $17,906,000 after acquiring an additional 28,436 shares during the last quarter. Finally, Hedeker Wealth LLC grew its position in Elanco Animal Health by 19.8% in the second quarter. Hedeker Wealth LLC now owns 99,010 shares of the company’s stock valued at $1,429,000 after acquiring an additional 16,358 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

Shares of ELAN opened at $12.81 on Friday. Elanco Animal Health has a 12 month low of $8.52 and a 12 month high of $18.80. The firm has a fifty day simple moving average of $15.97 and a 200 day simple moving average of $15.56. The stock has a market capitalization of $6.33 billion, a price-to-earnings ratio of -4.83, a PEG ratio of 1.29 and a beta of 1.42. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.95.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, May 8th. The company reported $0.34 EPS for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. The firm had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. The company’s revenue for the quarter was down 4.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.45 earnings per share. Research analysts forecast that Elanco Animal Health will post 0.93 EPS for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.